Notice Number: NOT-GM-19-041
Key Dates
Release Date: May 15, 2019
PAR-18-779 - Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)
PAR-19-061 -Computational Genomics and Data Science Opportunities for Small Business (R43/R44 Clinical Trial Not Allowed)
PA-19-043 - Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)
PA-19-034 - Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)
Issued by
National Institute of General Medical Sciences (NIGMS)
Purpose
The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications focused in the following areas:
- Improvement of methodology (technology) for genetic analysis (e.g., gene expression, probes), including procedures for the separation and analysis of nucleic acids and proteins as these relate to genetic problems.
- Improvement in procedures (statistical, computational, laboratory) for the analysis of gene flow and gene dynamics in human populations.
- Development of improved vectors for gene transfer.
- Development of tools and technologies to detect and monitor complex human phenotypes or traits.
- Improvement in procedures (statistical, computational, laboratory) for the high- and medium-throughput analysis of gene expression patterns and regulatory networks.
- Development or improvement of methods for high throughput detection of epigenomic changes.
- Development of improved or novel methodology for structure/function analysis of very large macromolecular complexes involved in transmission or expression of genetic material. Development of new or innovative tools and methods in bioinformatics and computational biology.
- Development of tools and technologies for a biomedical data science ecosystem for biomedical research. Technologies for findability, interconnectivity, and interoperability of biomedical data sets and resources, integration of existing data management tools and development of new ones, universalization of innovative algorithms and tools.
- Development of ontologies and modules useful for combining and mining databases containing genotype and phenotype information in order to discover correlations for drug effects, either therapeutic or adverse.
- Development of methods and strategies to characterize the function of kinases, ion channels and G-protein coupled receptors and development of cell signaling molecules and signaling intermediates, particularly those related to G-protein coupled receptors ultimately leading to the commercialization of understudied proteins identified in the "Illuminating the Druggable Genome" project.
Application and Submission Information
This Notice applies to application due dates on the dates indicated below and subsequent due dates through the expiration date of the FOA.
The following funding opportunity announcements (FOAs) must be used for submissions for this initiative. Although NIGMS is not listed as a Participating Organization in the FOAs listed below, applications for this initiative will be accepted.
Activity Code |
FOA |
First Available Due Date |
|---|---|---|
R43/R44 |
PAR-18-779, Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed) |
September 5, 2019 |
R43/R44 |
PAR-19-061, Computational Genomics and Data Science Opportunities for Small Business (R43/R44 Clinical Trial Not Allowed) |
September 5, 2019 |
R43/R44 |
PA-19-043, Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed) |
September 5, 2019 |
R43/R44 |
PA-19-034, Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed) |
September 5, 2019 |
All instructions in the SF424 (R&R) Application Guide and the listed funding opportunity announcements must be followed, with the following additions:
- For funding consideration, applicants must include "NOT-GM-19-041" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Inquiries
Please direct all inquiries to:
Scientific/Research Contact:
Dmitriy Krepkiy, Ph.D.
National Institute of General Medical Sciences
Email: dmitriy.krepkiy@nih.gov
Financial and Grants Management Contact:
Brian Iglesias
National Institute of General Medical Sciences
Email: iglesiab@mail.nih.gov
and Human Services (HHS)
